13F Holdings
中文EN

MGRX MANGOCEUTICALS, INC.

Services-Misc Health & Allied Services, NEC · Nasdaq · SEC CIK 1938046 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-35.6%
TTM net income YoY44.3%
TTM EPS YoY80.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin52.9%
Operating margin-2,608.1%
Net margin-3,673.7%
FCF margin—
EBITDA margin-2,607.7%

Returns

ROE-82.3%
ROA-69.8%
ROIC (approx.)-48.2%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets9.4%
Debt / equity0.00x
Current ratio1.28x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.34x
Accruals ratio-45.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue$456,021$615,873$731,493$8,939
Cost of revenue$54,422$93,296$154,900$4,089
Gross profit$250,386$379,964$431,501$4,850
SG&A expense$3.76M$3.00M$3.32M$1.64M
Operating income-$18.03M-$7.97M-$9.22M-$1.99M
Interest expense$103,513$13,700-$6,473$6,473
Pretax income-$20.64M-$8.71M-$9.21M-$2.00M
Net income-$20.64M-$8.71M-$9.21M-$2.00M
EBITDA-$18.03M-$7.96M-$9.19M-$1.99M
EPS (basic)-2.17-4.80-8.58-0.19
EPS (diluted)-2.17-4.80-8.58-0.19
Weighted avg. shares (diluted)10.07M1.98M1.07M10.80M
Balance sheet
Cash & equivalents$1.49M$58,653$739,006$682,860
Inventory——$18,501—
Current assets$1.55M$75,595$835,402$694,605
PP&E, net$1,794$2,806$96,129$117,499
Intangibles$14.23M$15.23M——
Total assets$16.09M$15.37M$1.05M$1.00M
Current liabilities$890,568$1.43M$211,078$260,577
Total liabilities$890,568$1.43M$276,039$389,257
Shareholders' equity$15.20M$13.95M$774,754$614,030
Shares outstanding15.89M3.25M1.43M13.37M
Cash flow statement
Operating cash flow-$5.85M-$4.86M-$7.00M-$1.35M
Capital expenditure——$3,519$43,102
Free cash flow——-$7.00M-$1.39M
Investing cash flow—$65,000-$3,519-$43,102
Financing cash flow$7.27M$4.13M$7.06M$2.05M
Depreciation & amortization$1,012$9,936$24,889$3,863
Stock-based compensation$1.17M$248,682$624,463$234,088

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.